C&L: Cortex names Varney new COO

Cortex Pharmaceuticals has named Mark Varney, Ph.D., as COO and chief scientific officer.

Sirtris Pharmaceuticals has hired Garen Bohlin as COO.

Ambit Biosciences has hired Donald R. Myll as senior vice president commercial operations and CFO.

Neurologix has hired Marc L. Panoff as CFO and chief accounting officer.

Nabi Pharmaceuticals CFO Mark Smith has announced he will resign effective March 1. Thomas E. Rathjen has been named vice president of investor relations.

IDM Pharma announced that Robert De Vaere will resign effective March 31 from his position as vice president, CFO and secretary.

Merrion Biopharma announced the appointment of Jonathan O'Connell as CFO.

Maneesh K. Arora will begin transitioning to the position of CFO of Third Wave Technologies. Gregory K. Hamilton, who has served as the company's executive director of planning and administration, has been appointed vice president of finance.

Peter Zundorf will become head of the oncology business area at Schering.

Biogen Idec has named Susan H. Alexander executive vice president, general counsel and corporate secretary.

Illumina has appointed Matthew L. Posard as vice president of marketing

Grant Life Sciences has named Indira R. Pottathil, Ph.D., director of international marketing.

Cephalon announced that Horst Witzel, Dr.-Ing., has decided to retire from the board of directors.

EraGen Biosciences has added three new directors: Greg Johnson, managing director of venture capital firm Prolog Ventures; Tracy Marshbanks, vice president of life sciences investment firm First Analysis; and Bruce Neviaser, general partner of angel investor Continuum Investment.

ImmuneRegen BioSciences has named James Robert Campbell, Ph.D., senior advisor to its Bioterrorism Preparedness Advisory Board.

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.